07th week of 2019 patent applcation highlights part 9 |
Patent application number | Title | Published |
20190046499 | CANNABIS-BASED BIOACTIVE FORMULATIONS AND METHODS FOR USE THEREOF - Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs. In some methods, the human subjects have been previously treated with one or more therapeutic agents such as, for example, antidepressants and antianxiety drugs, and have developed at least partial tolerance to the one or more therapeutic agents. | 2019-02-14 |
20190046500 | APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION - Disclosed is an application of substituted cinnamamide derivatives in the preparation of anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, R | 2019-02-14 |
20190046501 | Taxane Analogs for the Treatment of Brain Cancer - Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer. | 2019-02-14 |
20190046502 | APPLICATION OF OBACUNONE IN PREPARATION OF DRUG FOR PREVENTING AND TREATING LUNG DAMAGE AND PULMONARY FIBROSIS - Disclosed is application of obacunone in the manufacture of a medicament for prevention or treatment of lung injury and pulmonary fibrosis. The medicament consists of obacunone and pharmaceutically acceptable auxiliaries and additives, wherein obacunone is 3% to 25% by mass in the medicament. The obacunone in the medicament can inhibit bleomycin-induced lung injury and pulmonary fibrosis in mice, and regulate the expression of the inflammation-associated cytokines in the bleomycin-induced injured lung tissue in mice. | 2019-02-14 |
20190046503 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES - The present invention provides a compound belonging to furanocoumarin derivative having core structure (A) as given below, its pharmaceutically acceptable salt, isomer or a combination thereof for the treatment and/or prevention of a parasitic mediated disease. The present invention also provides a method for manufacturing and isolating said compound as well as method for treatment and prevention of parasitic mediated disease using said compound. In a preferred embodiment, the parasite is | 2019-02-14 |
20190046504 | MATERIALS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTION - The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity. | 2019-02-14 |
20190046505 | APREMILAST PHARMACEUTICAL COMPOSITIONS - The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions. | 2019-02-14 |
20190046506 | USE OF 5HT2A INVERSE AGONISTS FOR TREATING PSYCHOSIS - Disclosed herein are methods of using a 5-HT | 2019-02-14 |
20190046507 | COMPOUNDS FOR THE TREATMENT OF MALARIA - The present invention provides methods of treating malaria by administration of a compound of Formula (I): or a pharmaceutically acceptable salt of said compound, to a subject in need thereof, wherein the variables X, R1, R3, R4, R5, A, B, L, m and n are as defined herein. The invention also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin V activity, for treating a | 2019-02-14 |
20190046508 | COMBINATION THERAPIES FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING, AND ATHEROSCLEROSIS - Provided herein are combination therapies for the treatment of progeroid diseases and conditions, cellular aging, bone diseases, and cardiovascular diseases. The provided combination therapies target the aberrant farnesylation of the mutant lamin A protein progerin and increase progerin clearance. | 2019-02-14 |
20190046509 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy. | 2019-02-14 |
20190046510 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 2019-02-14 |
20190046511 | ENDOPARASITE CONTROL AGENT - The present invention is intended to provide a novel parasiticide, antiprotozoal or other endoparasite control agents which are effective for controlling animal endoparasites that have been impossible to control by conventional ones. Provided is an endoparasite control agent comprising, as an active ingredient, a carboxamide derivative represented by the general formula (I): | 2019-02-14 |
20190046512 | IDH1 INHIBITORS FOR THE TREATMENT OF HAEMATOLOGICAL MALGNANCIES AND SOLID TUMORS - Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation. | 2019-02-14 |
20190046513 | COMBINATION THERAPIES OF HDAC INHIBITORS AND TUBULIN INHIBITORS - Provided herein are combinations that include a histone deacetylase inhibitor and tubulin inhibitor such as eribulin or a pharmaceutically acceptable salt thereof that are useful for treating cancer, including reducing cancer metastasis. | 2019-02-14 |
20190046514 | USE OF STATIN-BASED DRUG FOR TREATMENT OF EML4-ALK-POSITIVE NON-SMALL CELL LUNG CANCER RESISTANT TO ALK INHIBITOR - Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer. | 2019-02-14 |
20190046515 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2019-02-14 |
20190046516 | TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRODOPIDINE - The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject. | 2019-02-14 |
20190046517 | METHODS AND COMPOSITIONS FOR TREATMENT OF MITOCHONDRIAL TOXICITY - The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug. | 2019-02-14 |
20190046518 | METHODS FOR USING FXR AGONISTS - The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases. | 2019-02-14 |
20190046519 | METHODS FOR USING FXR AGONISTS - The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases. | 2019-02-14 |
20190046520 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF - Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity. | 2019-02-14 |
20190046522 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 2019-02-14 |
20190046524 | METHODS OF TREATING RADIATION INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND RELATED DISEASE STATES USING COMPOUND 512 - The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof. | 2019-02-14 |
20190046525 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES - Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor. | 2019-02-14 |
20190046526 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE - Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): | 2019-02-14 |
20190046527 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS - The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. | 2019-02-14 |
20190046528 | METHOD OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH BY USING PHOSPHODIESTERASE 3 INHIBITOR - Provided herein is a method of preventing hair loss or promoting hair growth, the method including administering an effective amount of a PDE 3 inhibitor. More particularly, when the method of the present disclosure is used, an excellent hair loss prevention or hair growth promotion effect is obtained by inhibiting the activity of PDE 3. | 2019-02-14 |
20190046529 | INCREASING EXPRESSION OF INTERFERON REGULATED GENES WITH COMBINATONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS - Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor. | 2019-02-14 |
20190046530 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS - Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. | 2019-02-14 |
20190046531 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH - The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer). | 2019-02-14 |
20190046532 | PSYCHIATRIC TREATMENT FOR PATIENTS WITH GENE POLYMORPHISMS - The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone. | 2019-02-14 |
20190046533 | Combination therapy for the treatment of cancer - The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof. | 2019-02-14 |
20190046534 | Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile - The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2019-02-14 |
20190046535 | THERAPEUTIC THIOPHENE-, FURAN-, AND PYRIDINE-FUSED AZOLOPYRIMIDIN-5-(6H)-ONES - Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders. | 2019-02-14 |
20190046536 | Combination Therapy - The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-N3pGlu Abeta antibody selected from the group consisting of hE8L, Antibody I, and Antibody II. | 2019-02-14 |
20190046537 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE - Disclosed are compounds of general formula (I): | 2019-02-14 |
20190046538 | METHODS FOR TREATING GI SYNDROME AND GRAFT VERSUS HOST DISEASE - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 2019-02-14 |
20190046539 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEUROPATHIC PAIN ASSOCIATED WITH GUILLAIN-BARRE SYNDROME | 2019-02-14 |
20190046540 | TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY - Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog. | 2019-02-14 |
20190046541 | ACETAMIDE THIENOTRIAZOLODIAZEPINES AND USES THEREOF - The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception. | 2019-02-14 |
20190046542 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2019-02-14 |
20190046543 | METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT - Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R | 2019-02-14 |
20190046544 | OMEGA-3 COMPOSITIONS - The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives. | 2019-02-14 |
20190046545 | COMPOSITIONS WITH SPECIFIC OLIGOSACCHARIDES TO PREVENT LATER IN LIFE OBESITY OR RELATED COMORBIDITIES, BY INCREASING COLONIC SCFA PRODUCTION AND/OR BY INCREASING GLP-1 SECRETION - The present invention relates to a nutritional composition comprising an oligosaccharide mixture, said oligosaccharide mixture comprising at least one N-acetylated oligosaccharide, one galacto-oligosaccharide and one sialylated oligosaccharide for use in reducing and/or avoiding excessive fat mass accumulation and/or in preventing any related later in life health disorders in an infant or a young child such as later in life obesity and related comorbidities, by increasing colonic SCFA production and/or GLP-1 secretion/releasein said infant or young child. | 2019-02-14 |
20190046546 | SYNTHETIC COMPOSITION FOR MICROBIOTA MODULATION - This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation. | 2019-02-14 |
20190046547 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC WOUNDS - The described invention provides pharmaceutical compositions and methods for treating chronic non-healing wounds. The pharmaceutical compositions of the described invention comprise a granulated sugar and a hydrogel biomaterial. | 2019-02-14 |
20190046548 | Formulation and Manufacturing Method for Color-Changing Eyedrops - Disclosed is a formulation and a manufacturing method for color-changing eyedrops. | 2019-02-14 |
20190046549 | USE OF TREHALOSE FOR TREATMENT OF NEUROLOGICAL DISEASES - The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be about 2.67 g/kg/day. A method for treating a neurological disorders is disclosed which involves administering trehalose to a subject as a single daily administration with a daily dose between about 0.25 to about 12.5 g/kg/day and in an embodiment of this method the daily dose is about 2.67 g/kg/day. Also disclosed herein is the use of trehalose in the manufacture of a medicament for treatment of neurological disorders, wherein the trehalose is formulated as a single daily dose with the trehalose present in the medicament in an amount of between about 0.25 to about 12.5 g/kg/day. In an embodiment the daily dose is about 2.67 g/kg/day. The present disclosure provides a pharmaceutical composition for treating neurological disorders, comprising a daily dose of trehalose, and a pharmaceutically acceptable carrier wherein the daily dose of the trehalose is between about 0.25 to about 12.5 g/kg. The trehalose may be formulated as part of a foodstuff. | 2019-02-14 |
20190046550 | TOPICAL COMPOSITION FOR TREATMENT AND/OR PROPHILAXIS OF MASTITIS AND/OR EDEMA - The present invention relates to a topical composition which is mixture of natural ingredients of plant and animal origin, to the process of its preparation, to its use for treatment and/or prophylaxis of mastitis and/or edema in female mammals, more particularly to its use for treatment and/or prophylaxis of mastitis and/or udder edema in dairy animals. The topical composition according to the invention is mixture of natural ingredients of plant and animal origin, wherein the topical composition comprises: sugar, carboxylic acid solution, egg white and vehicle. | 2019-02-14 |
20190046551 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER - The present invention provides a novel pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, a polynucleotide derived from various miRNAs associated with cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing cancer in a subject having the cancer using the pharmaceutical composition or the combination drug. The present invention relates to a pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, a polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 1, or a nucleotide sequence comprising a substitution of one nucleotide in the nucleotide sequence as set forth in SEQ ID NO: 1 (wherein when at least a part of the polynucleotide is DNA, uracil in a region corresponding to the DNA in the nucleotide sequence is replaced with thymine). | 2019-02-14 |
20190046552 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HCV INFECTION - In one aspect, the present invention features a method of treating a subject infected with the Hepatitis C virus, the method comprising administering to the subject a pharmaceutical composition comprising a compound of Formula (I) at a dosage of about 10 mg to about 1500 mg, wherein the compound is selected from Formula Ia, Formula Ib, and Formula Ic, or a prodrug or pharmaceutically acceptable salt thereof to thereby treat the subject. In another aspect, the present invention features a kit comprising a pharmaceutical composition comprising the compound of Formula (I). In some embodiments, the kit further comprises an additional agent or treatment. | 2019-02-14 |
20190046553 | MATERIALS AND METHODS FOR THE TREATMENT OF VASCULAR DISEASE - The invention provides a method of treating a vascular condition within a subject comprising administering a therapeutic agent to said subject that is capable of modulating the expression levels of a long non-coding RNA (IncRNA) selected from the group consisting of lncRNA2, lncRNA4, lncRNA5, lncRNA6, ncRNA7 and ncRNA8 as defined in | 2019-02-14 |
20190046554 | CONTROL AND CHARACTERIZATION OF MEMORY FUNCTION - Provided herein are devices and methods for reversibly controlling memory function in living non-human animals. Some variations of methods for affecting memory function comprise temporarily inhibiting neurons of the hippocampus (e.g., neurons of the dorsal CA1 field of the hippocampus) during the acquisition or retrieval of a memory. Alternatively or additionally, methods for reversibly affecting memory function comprise inhibiting neurons of the amygdala (e.g. basolateral amygdala) and/or neurons of the cingulate cortex (e.g., anterior cingulated cortex). Methods for disrupting the formation and recall of memories by inhibiting excitatory neurons expressing light-activated proteins are disclosed herein. One or more methods for reversibly affecting memory function described herein can be used to evaluate the effectiveness of pharmacological agents in treating PTSD and/or various memory disorders. | 2019-02-14 |
20190046555 | CONJUGATED ANTISENSE COMPOUNDS FOR USE IN THERAPY - Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human. | 2019-02-14 |
20190046556 | Methods and Pharmaceutical Compositions for the Prophylactic Treatment of Peritoneal Carcinomatosis - The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of peritoneal carcinomatosis. In particular, the present invention relates to a method for the prophylactic treatment of peritoneal carcinomatosis in a patient in need thereof comprising administering to the patient a therapeutically effective combination of at least one dextrin polysaccharide and at least one chemotherapeutic agent. | 2019-02-14 |
20190046557 | CANCER TREATMENT USING BETA-(1-3)-(1-4)-GLUCAN - A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a β-( | 2019-02-14 |
20190046558 | COMPOSITION AND METHODS OF INHIBITING AMYLASE-MEDIATED HYDROLYSIS OF ALPHA (1 to 4)-LINKED GLUCOSE POLYMERS - PAZ320, a mixture of two galactomannans (GMa and GN/IPβ), is being developed to treat diabetes and inflammatory diseases. Both GMα and GMβ have a β(1->4) mannan backbone, with a high density of α(1->6) linked galactose units. When ingested by diabetic patients, PAZ320 reduces the magnitude of postprandial glucose excursions. PAZ320 functions by binding to enzymes that hydrolyze starch in the gastrointestinal track and thereby reduces steady-state concentrations of low molecular weight sugars like glucose. PAZ320 binds to the α-amylase enzyme from human and porcine sources and thereby attenuates the rate of amylase-mediated hydrolysis of α(1->4)-linked glucose polymers (starch and maltohexaose). | 2019-02-14 |
20190046559 | GEL FORMULATION FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISTRESS IN HORSES AND OTHER SPECIES - Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals are disclosed. The supplement is in a gel form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal with the gel at least once daily. | 2019-02-14 |
20190046560 | LIPIDATED PSA COMPOSITIONS AND METHODS - The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof. | 2019-02-14 |
20190046561 | BARRIERS FOR GLASS AND OTHER MATERIALS - Embodiments described herein generally relate to articles and methods for containing compositions comprising hydrogen gas. In some embodiments, the article comprises a container that comprises glass. In some cases, the container may further comprise TiO | 2019-02-14 |
20190046562 | MEDICATION ENHANCEMENT USING HYDROGEN - Embodiments described herein generally relate to medicinal compositions (e.g., compositions comprising an active pharmaceutical agent) such as those comprising liquid hydrogen and/or hydrogen gas. In certain embodiments, the composition comprises hydrogen and/or noble gas(es) in a medicinal composition, for example, within the aqueous phase (e.g., dissolved). For example, in some cases, the medicinal composition may comprise an active pharmaceutical ingredient and hydrogen (H | 2019-02-14 |
20190046563 | NANOBUBBLE-CONTAINING COMPOSITION AND USE THEREOF - A composition contains nanobubbles containing hydrogen, oxygen, and nitrogen, and the use thereof. A composition containing, as an active ingredient, nanobubbles having a diameter of 30 micrometer or less and containing 0.45-0.55 ppm of hydrogen, 10-12.5 ppm of oxygen, and 7-8 ppm of nitrogen. A mitochondria-activating composition, cell growth promoting agent, cell preservation liquid or cryopreservation liquid containing this composition, and a method for using this composition, agent, or liquid. A food or beverage, or a food or beverage raw material, produced using this composition. | 2019-02-14 |
20190046564 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY ARTHRITIS - Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. | 2019-02-14 |
20190046565 | PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME - Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions. | 2019-02-14 |
20190046566 | INTRA-ARTICULAR ADMINISTRATION OF POLYMETAPHOPSPHATES FOR THE TREATMENT OF CRYSTAL ARTHROPATIES - The invention relates to the use of polymetaphosphates for intraarticular application for the treatment of microcrystalline arthropathies. The preparation comprises a diluent water solution and a linear or cyclic polymetaphosphate in lyophilized powder, in which the volume of diluent solution and the weight/volume ratio of lyophilized polymetaphosphate powder and diluent solution are comprised within defined fields, and the treatment is carried out by step-wise lavage, i.e. using in succession a plurality of defined portions of reconstituted solution for a joint lavage, or by continuous lavage. | 2019-02-14 |
20190046567 | Therapeutic Detoxification Compositions and Methods of Making and Using Same - A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin. | 2019-02-14 |
20190046568 | METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS - The present disclosure provides partially mature and activated dendritic cells that produce levels of cytokines/chemokines, for example, one or any combination of and/or all of IL-6, IL-8, IL-12 and/or TNFα, that are correlated with improved clinical outcomes, significantly increased survival times and significantly increased times to tumor or cancer recurrence. The determined threshold amounts of these cytokines can be used for (i) a immunotherapeutic potency test for activated dendritic cells, (ii) selecting responder patients, (iii) rejecting non-responder patients, and (iv) to screen for dendritic cell activation or maturation agents that can also induce the production of the threshold amount of the cytokines/chemokines. | 2019-02-14 |
20190046569 | IMMUNE STIMULATORY FUNCTION AND ANTI-TUMOR ACTIVITY OF TGF- PRIMED MYELOID DERIVED SUPPRESSOR CELLS (MDSC) - Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-β1, and in specific embodiments the exposure to TGF-β1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity. | 2019-02-14 |
20190046570 | Compositions and Methods for Recombinant CXADR Expression - Recombinant expression of CXADR in a cell, and especially an immune competent cell is employed to enable or improve gene delivery to the cell by an adenovirus. In particularly preferred aspects, the immune competent cell is a an NK cell, a T-cell, a B-cell, a macrophage, or a dendritic cell, and the gene delivery comprises a recombinant nucleic acid encoding a disease-specific antigen, such as a patient specific neoepitope or a tumor associated antigen. | 2019-02-14 |
20190046571 | T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF - The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCRαβ-deficient T cells and CD3/TCRαβ-deficient chimeric antigen receptor T cells that express such PEBLs. | 2019-02-14 |
20190046572 | COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE - The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant. | 2019-02-14 |
20190046573 | PROCESS FOR OBTAINING A SPRINKLING COMPOUND OF MICROVASCULAR ENDOTHELIAL SKIN CELLS AND MESENCHYMAL STEM CELLS AND METHOD OF APPLICATION FOR TISSUE REGENERATION - The invention relates to a process for obtaining a cellular sprinkling compound and to the respective method of application to provide a therapeutic treatment for skin injuries, based on the implantation, by sprinkling and/or spraying, of human mesenchymal stem cells and microvascular endothelial cells that have been pre-expanded in vitro and resuspended in a regenerative solution for cellular implantation of biocompatible biomaterials. The solution is formed by blood plasma rich in growth factors obtained from the patient to be treated and, in some cases, by medical-grade type I collagen and by medical-grade hyaluronic acid, which potentiates the regeneration, re-epithelialization, and reconstruction of skin tissue. | 2019-02-14 |
20190046574 | Placenta-derived multipotent stem cells - Novel isolated stem cells derived from pre-term placental tissue and compositions comprising the stem cells are provided as well as use of the compositions for therapy, research and diagnosis. The cells and compositions are useful in treating Myelomeningocele (MCC), spina bifida (SB) or spinal cord injury or paralysis. | 2019-02-14 |
20190046575 | METHODS OF TREATING OR PREVENTING RESPIRATORY CONDITIONS - The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1 | 2019-02-14 |
20190046576 | ADIPOSE TISSUE DERIVED MESENCHYMAL STROMAL CELL CONDITIONED MEDIA AND METHODS OF MAKING AND USING THE SAME - Provided herein are lyophilized compositions containing the secretome of cultured adipose cells, pharmaceutical compositions and that additionally contain a sustained release drug delivery matrix, as well as methods of making and using such compositions. | 2019-02-14 |
20190046577 | METHODS OF PRODUCING ACTIVATED MESENCHYMAL STEM CELLS - The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs). | 2019-02-14 |
20190046578 | METHODS AND COMPOSITIONS FOR EXPANDING LONG-TERM HEMATOPOIETIC STEM CELL POPULATIONS - The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation. | 2019-02-14 |
20190046579 | TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES - Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided. | 2019-02-14 |
20190046580 | COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS - Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies. | 2019-02-14 |
20190046581 | COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS - Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies. | 2019-02-14 |
20190046582 | USE OF ANTI-AGING GLYCOPROTEIN FOR ENHANCING SURVIVAL OF NEUROSENSORY PRECURSOR CELLS - The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate thereof: (I). | 2019-02-14 |
20190046583 | COMPOSITIONS AND METHODS FOR NEURALGENESIS - The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier. | 2019-02-14 |
20190046584 | IMPROVED PREPARATIONS OF ADULT LIVER PROGENITOR CELLS - Preparations of adult liver progenitor cells (called HHALPCs) have been manufactured from different human donors and characterized by using cell surface markers that allow identifying HHALPCs preparations and/or the methods for producing them that are most suitable for cell therapy, in particular for treating liver diseases or inherited blood coagulation disorders. | 2019-02-14 |
20190046585 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein. | 2019-02-14 |
20190046586 | Method and System for Repairing Damaged Tissue Using Nucleated Plasma Particles (Nuc-P2s) and Mesodermal Stem Cells (MesoSCs) - The current invention is a method and system for optimally isolating adult derived stem cells from whole blood and reintroducing the adult derived stem cells into a subject at specific target areas having damaged tissue to be repaired. | 2019-02-14 |
20190046587 | NERVE GROWTH PROMOTER AND METHOD FOR PRODUCING SAME, INTERNAL PREPARATION, MEDIUM ADDITIVE, CELL DILUTION ADDITIVE, MEDIUM, CELL DILUTION, ANTIOXIDANT AND METHOD FOR PRODUCING SAME, EXTERNAL PREPARATION, AND WOUND TREATMENT AGENT AND METHOD FOR PRODUCING SAME - A nerve growth promoter and an antioxidant containing a degradation product obtained by degrading a composition containing a hyaluronic acid and a protein with a protease. A would treatment agent containing an ethyl acetate extract of a degradation product obtained by degrading a composition containing a hyaluronic acid and a protein with a protease. | 2019-02-14 |
20190046588 | IMMUNOSTIMULATORY BACTERIA FOR THE TREATMENT OF CANCER - Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 | 2019-02-14 |
20190046589 | Compositions for Fecal Floral Transplantation and Methods for Making and Using Them and Devices for Delivering Them - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or | 2019-02-14 |
20190046590 | Compositions of Microbiota and Methods Related Thereto - Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as | 2019-02-14 |
20190046591 | HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases. | 2019-02-14 |
20190046592 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 2019-02-14 |
20190046593 | COMPOSITIONS FOR TREATING CANDIDIASIS INFECTIONS - The present invention relates to a composition comprising as antifungal active agent at least 2·10 | 2019-02-14 |
20190046594 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS - Recombinant herpes simplex virus (HSV)-1 capable of selectively replicating in alternative lengthening of telomeres (ALT)-dependent tumor cells are described. The recombinant HSV-1 are ICP0-deficient, such as by complete deletion of the ICP0 gene, or mutation of the ICP0 gene sufficient to diminish or eliminate E3 ubiquitin ligase activity of ICP0. In some cases, the recombinant HSV-1 further include additional gene deletions or mutations, such as those that render the virus glycoprotein C (gC) deficient, or include a heterologous gene, such as a gene encoding an immunostimulatory molecule. Methods of treating ALT-dependent cancer, and methods of selectively killing ALT-dependent tumor cells are also described. | 2019-02-14 |
20190046595 | METHODS OF USING SMECTITE COMPOSITIONS FOR TREATING CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES AND SYMPTOMS - Provided herein are compositions useful for the treatment or prevention of | 2019-02-14 |
20190046596 | Cannabinoid Enriched Creamer Composition - The present invention is a cannabinoid enriched creamer composition and kit for human consumption, the composition includes by weight about thirty-five point three-three percent (35.33%) coconut oil, about thirteen point five-eight percent (13.58%) ghee, about thirty-two point six percent (32.6%) goats milk powder, about five point eight-five percent (5.85%) vanilla powder, about one point three-four percent (1.34%) stevia extract, about point three-eight percent (0.38%) sunflower lecithin, and about ten point nine two percent (10.92%) cannabinoid in a liquid state. | 2019-02-14 |
20190046597 | OBESITY TREATMENT - A method for treating the onset of obesity, reducing dyslipidemia and improving insulin sensitivity in mammals comprising administering a therapeutically effective amount of dried alcoholic extract of | 2019-02-14 |
20190046598 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES - The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials. | 2019-02-14 |
20190046599 | GROWTH PROMOTING PEPTIDES AND USES THEREOF - A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQUENCE ID NO's: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQUENCE ID NO'S 15 to 505, and 546 to 704. | 2019-02-14 |
20190046600 | COMPOSITIONS AND USES THEREOF - The present invention relates to compounds capable of modulating the activity of poly(ADP-ribose) polymerase 1 (PARP-1) and/or lactate dehydrogenase A (LDHA) and uses thereof. | 2019-02-14 |